AstraZeneca's drug Fasenra flops in COPD trial

LONDON (Reuters) - AstraZeneca's said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

We report two asthmatic patients who presented in the emergency department for an asthma exacerbation. The first patient developed hyperlactatemia at 3.9 mmol/L and the second patient developed hyperlactatemia at 5.6 mmol/L after terbutaline treatment. Both patients had a favorable outcome after adjusting the aerosol dose to clinical parameters. DISCUSSION: Lactic acidosis induced by the use of inhaled β2 agonists is not synonymous of clinical deterioration. However, this side effect may be complicated by a tachypnea compensating for metabolic acidosis and should be known to avoid unnecessary therapeutic...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Study Objectives:To investigate the association between non-apnea sleep disorders (NSD) and subsequent benign paroxysmal positional vertigo (BPPV) risk.Methods:This retrospective cohort study was conducted using the Taiwan National Health Insurance Research Database from 2000 to 2013. We established an NSD group (n = 24,624) and an age-, sex- and index year-matched comparison group (n = 98,496). The primary outcome was the occurrence of BPPV. The incidence rates of BPPV in the two cohorts were compared with a 14-year follow-up. Cox proportional hazard regression analysis was used to evaluate the effects of NSD on BPPV risk...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Take this short 5-question quiz to find out what you know--or, what you may have missed--about the latest developments in COPD.
Source: ConsultantLive - Category: Internal Medicine Authors: Tags: COPD Quiz Source Type: news
Researchers investigated  whether first-line chemotherapy improved overall survival in NSCLC patients with severe to very severe COPD.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We examined annual costs through 5 years, standardized to 2016 dollars, using multivariate regression models, controlling for site and baseline patient factors.ResultsIn the first year, including the CABG surgery, annual average costs were $66,599 (SE, $1,946) for the on-pump group and $70,552 (SE, $1,954) for the off-pump group. In years 2 to 5, average costs ranged from $15,000 to $20,000 per year. There was no significant difference between on-pump and off-pump across the 5 years. We explored differences among high-risk subgroups (diabetes, chronic obstructive pulmonary disease, peripheral vascular disease, cerebrovascu...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
(MedPage Today) -- Symptoms of undertreated HF are too often confused with COPD
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
Conclusion: The SVS represents a novel approach for the treatment of severe emphysema with a clinically acceptable risk-benefit profile.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Conclusions: Presenting initial respiratory symptoms was the common cause for medical consultation in patients undergoing lung cancer surgery. Patients with lung cancer in larger tumor size or squamous cell carcinoma more likely presented initial and even multiple initial respiratory symptoms.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Annals of the American Thoracic Society,Volume 15, Issue Supplement_4, Page S227-S233, December 2018.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
Annals of the American Thoracic Society,Volume 15, Issue Supplement_4, Page S234-S238, December 2018.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine